More than one-third of patients with IBD are affected by extraintestinal manifestations or extraintestinal complications beyond the intestinal manifestation of the disease. The most common ...

AUSTIN, Texas — Approximately 30% of patients with inflammatory bowel disease developed new or worsening extraintestinal manifestations after receiving Entyvio, according to data presented at Crohn’s ...

This article focuses on the clinical implications of extraintestinal manifestations involving the musculoskeletal system, eyes, and skin, including issues in diagnosis and treatment. Paul E. Evans, MD ...

Please provide your email address to receive an email when new articles are posted on . Extraintestinal manifestations were more common in women (OR = 1.2), Crohn’s (OR = 1.7) and among those who ...

A connection between extraintestinal infections and food is possible, but it is hard to prove a direct link, according to a Dutch agency. Extraintestinal infections arise outside the intestines, ...

Currently in Phase III of clinical trials, Sanofi is expected to commercialize vaccine candidate. Sanofi announced in a company press release that it has agreed to terms with Janssen, a Johnson & ...

Coeliac disease is often accompanied by extraintestinal manifestations, which can be the result of aberrant immune responses but also malabsorption These concurrent conditions can affect various ...

Vedolizumab (Entyvio) and ustekinumab (Stelara) appear to be equally effective for extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD), according to results of a retrospective ...

Ulcerative colitis (UC), a form of inflammatory bowel disease (IBD), is often associated with extraintestinal complications — those that occur in other parts of the body, such as the skin, eyes, and ...

Sanofi is set to pay $175 million upfront to Janssen, followed by development and commercial milestones. Extraintestinal pathogenic E. coli (ExPEC) is a main bacterial cause of sepsis, a chronic and ...

Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t demonstrate sufficient efficacy in preventing invasive E. coli disease No safety signals related to ...